Skip to main content

Table 3 Guidelines and policy

From: Hepatitis C virus infection in Irish drug users and prisoners – a scoping review

  Date and author Setting Sample (n) Data collection Design Main results
[67] 2004 Dublin Area Hepatitis C Initiative Group ERHA GPs 2001–2002 Descriptive study reporting on HCV management guideline development for GPs The guidelines cover advice to GPs on all aspects of care of patients at risk of HCV, including
• general and preventative care
• care of other bloodborne and hepatotoxic viruses
• factors to be considered and appropriate evaluation prior to referring a patient for assessment at a hepatology unit.
[66] 2004
Hepatitis C Scientific Advisory Subgroup of the Blood Borne Virus Forum and the Eastern Regional Health Authority
ERHA 16 workshops with service planners, health and social care professionals and service users (70 2004 A regional hepatitis C strategy document using open space technology Reported on:
• health promotion
• role of the media
• service provision
• research, policy and planning
• education and training,
• liaison
• key workers
• co-ordination and collaboration
• accessing services
• psychological and complementary therapies
[72] 2006 Long National Drug users 1995–2005 Review Reports on
• 9 prevalence studies
• 7 studies identifying risk factors
[70] 2009 IPS Dublin Prisoners Guidelines Provide prisoners
• general health information
• advice and testing
• referral to appropriate specialist services in relation to HCV where clinically indicated
• treatment and support for those chronically infected.
[14] 2012 HSE National PWID & prisoners 2007 First national strategy • Reviewed and updated recommendation from the 2004 ERHA report.
• Developed 36-point action plan Prioritising recommendations for 2011–2012 in the areas of HCV surveillance, education, prevention and treatment.
[68] 2014 DOH National HCV infected patients Guidelines Recommendations:
• HSE establish a Hepatitis C Treatment Programme with a strong governance and management structure
• Provide drug treatment to those with greatest clinical need as a priority and treat as many patients as possible with the available resources
[69] HSE 2017 National    OST Guidelines • All drug users (including non-PWID) should be screened for HCV.
• Anti-HCV patients should be tested for HCV-antigen and LFTs
• all antigen positive patients should be referred to specialist services for PCR, fibroscanning and consideration for treatment.
• All patients at risk of HCV infection should be given information and advice on the disease and how it is transmitted.
• IDU and alcohol misuse should not exclude patients from treatment.
• Risks of concurrent alcohol use should be explained to anti-HCV patients.